

NCT ID	NCT06253520
Title	Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
Phase	Phase 1
Date Added	2024-02-12
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Aldesleukin, Cyclophosphamide, Fludarabine
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06218914
Title	A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation
Phase	Phase 1
Date Added	2024-01-23
Location	California, United States Florida, United States Illinois, United States Kansas, United States Missouri, United States New York, United States Pennsylvania, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06185556
Title	COLD FIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases
Phase	Phase 2
Date Added	2023-12-29
Location	Netherlands
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06176885
Title	Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
Phase	Phase 2
Date Added	2023-12-20
Location	China
Prior IO Allowed	No
CRC-directed	Yes

Status	Recruiting
Drugs	Camrelizumab
Tags	MSS/ MMRp
NCT ID	NCT06152523
Title	Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer
Phase	Phase 2
Date Added	2023-11-30
Location	France
Prior IO Allowed	No
CRC-directed	Yes
Status	Not yet recruiting
Drugs	Monalizumab/MEDI5257
Tags	MSI-H/ MMRd
NCT ID	NCT06149481
Title	Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
Phase	Phase 1, Phase 2
Date Added	2023-11-29
Location	Maryland, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	N-803, Retifanlimab, SX-682
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06120127
Title	Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally Recurrence
Phase	Phase 2
Date Added	2023-11-07
Location	China
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Recruiting
Drugs	Chemotherapy, PD-1 antibody
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT06107413
Title	Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
Phase	Phase 2
Date Added	2023-10-30

Location	Arizona, United States Arkansas, United States California, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Louisiana, United States Minnesota, United States North Carolina, United States Oregon, United States South Carolina, United States South Dakota, United States Texas, United States Virginia, United States Belgium Germany Israel Japan South Korea Spain Taiwan
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	ABBV-400, Bevacizumab, fluorouracil, Folinic acid, Irinotecan
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT06106308
Title	Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Phase	Phase 2
Date Added	2023-10-30
Location	Arizona, United States Arkansas, United States California, United States Florida, United States Hawaii, United States Indiana, United States Kansas, United States Michigan, United States Minnesota, United States Missouri, United States Nevada, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States Tennessee, United States Texas, United States Utah, United States Virginia, United States Washington, United States Wisconsin, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Bevacizumab, FOLFIRI, FOLFOX, Onvansertib
Tags	MSS/ MMRp

NCT ID	NCT06105021
Title	Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Phase	Phase 1, Phase 2
Date Added	2023-10-27
Location	California, United States Connecticut, United States New York, United States Oregon, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States
Prior IO Allowed	Yes
CRC-directed	Yes
Status	Active, not recruiting
Drugs	AFNT-211
Tags	MSI-H/ MMRd, MSS/ MMRp